Understand the source comparison
Best FOXO4-DRI Dosage for Cellular Renewal: Protocol Comparison
Acute Senolytic Clearance 20–25mg/kg Every 48 hours 10–14 days (6 injections) High baseline senescence burden, post-chemotherapy models, acute tissue injury Gold standard for rapid clearance; expect 40–60% reduction in p16-positive cells within two weeks. Risk
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Acute Senolytic Clearance
- 20–25mg/kg
- Every 48 hours
- 10–14 days (6 injections)
- High baseline senescence burden, post-chemotherapy models, acute tissue injury
- Gold standard for rapid clearance; expect 40–60% reduction in p16-positive cells within two weeks. Risk of transient immune suppression at doses >25mg/kg.
- Maintenance Prevention
- 5–10mg/kg
- Every 72–96 hours
- Ongoing (weeks to months)
- Aging models, chronic low-grade senescence, prevention studies
- Lower peaks reduce off-target effects; clearance rates plateau at 25–35% but sustained over time. Ideal for long-term interventions where injection frequency is a constraint.
- Intensive Twice-Daily
- 8–12mg/kg
- Every 8–12 hours
- 7–10 days
- Research requiring continuous senolytic pressure, short study windows, tissue-specific targeting
- Maintains stable plasma levels; highest consistency in dose-response across subjects. Injection burden limits practical use to controlled settings. Clearance comparable to acute protocols with fewer peak-related side effects.
- Low-Dose Exploratory
- 2–5mg/kg
- Every 48–72 hours
- 3–4 weeks
- Initial dose-finding studies, species with unknown FOXO4-DRI sensitivity, preliminary safety assessments
- Rarely achieves >20% senescent cell clearance; useful for establishing baseline tolerability before escalating. Not recommended as a therapeutic protocol. Primarily a safety screen.
- Each protocol demands purity verification (≥98%) and pH-adjusted reconstitution (7.0–7.4) to achieve stated outcomes. Dose calculations assume actual peptide content, not total lyophilised mass.